Table 9.
Clinical features | Age/Sex | CD4+ Cell Count(cells/mcL) | Type of GBS | Therapy | Status |
Ascending paraparesis | 23 y/M | 335 | AIDP | IVIG | Improved |
| |||||
Quadriplegia requiring ventilator | 30 y/M | 420 | AIDP | IVIG | Improved |
| |||||
Ascending weakness with neck muscle involvement | 45 y/M | 450 | AMAN | Steroids | Improved |
| |||||
Quadriplegia | 35 y/M | 204 | AMSAN | Nil | Mild improvement |
| |||||
Descending weakness with lower cranial nerve palsies | 34 y/M | 195 | AMSAN | Nil | Mild improvement |
| |||||
Quadriparesis | 33 y/M | 456 | AIDP | Steroids | Improved |
| |||||
Ascending muscle weakness | 35 y/F | 400 | AMAN | IVIG | Mild improvement |
| |||||
Paraparesis | 42 y/M | 450 | AIDP | Nil | Not available |
GBS = Guillain-Barré syndrome; IVIG = intravenous immunoglobulin; AIDP = acute inflammatory demyelinating polyradiculoneuropathy; AMAN = acute motor axonal neuropathy; AMSAN = acute motor and sensory axonal neuropathy